October 24, 2020

The Psychopharmacology Update Virtual platform will close on 12/24/20 at midnight

CLICK HERE for more Psychiatry CME


The American Board of Psychiatry and Neurology has reviewed the 2020 Psychopharmacology Update and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of maintenance of certification (MOC). The activity awards 6.0 AMA PRA Category 1 CreditsTM and 6.0 Self-Assessment Category 1 CME credits.

Overview of the 19 th Annual Psychopharmacology Update

This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover DRUG SELECTION IN PSYCHOPHARMACOLOGY: AN EVIDENCE-BASED APPROACH. New for this year are pre-conference workshops on addiction and medical cannabis. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.

Who Should Attend:
The 2020 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, neuropsychiatrists, pharmacists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders.

Continuing Medical Education

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 11.5 AMA PRA Category 1 CreditsTM (6.0 for the general program and 5.5 AMA PRA Category 1 Credits for completing the pre- conference workshops). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.



Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 11.5 (6 for the general sessions and 5.5 for attending the pre-conference workshops) contact hours. Up to 7.25 Pharmacotherapy contact hours (4.25 for the general sessions and 3 for the workshop.) for Advance Practice Registered Nurses will be indicated on your certificate.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 11.5 contact hour(s) (0.115 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number
UAN (Live): JA4008162-9999-20-2286-L01-P
UAN (Enduring): JA4008162-9999-20-2287-H04-P

Type of Activity: Knowledge

Hardware/Software Requirements (Required for Internet-based ACPE activities only)

Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.

Policy on Privacy and Confidentiality (Required for Internet-based ACPE activities only)
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

At the conclusion of this activity, clinicians should be better able to:

  • Explain the neurobiology of addiction and how it can inform treatment.
  • Describe special needs and issues related to the pregnant addicted patient, adolescent and elderly addicted populations, and patients with comorbid psychiatric disorders.
  • Explain data on the use of cannabis for medical disorders (randomized placebo-controlled trials)
  • List safety issues regarding cannabis use in medical disorders
  • Describe risks of CBD, especially that purchased online or from retailers
  • List reasons for using Telepsychiatry during the COVID Pandemic
  • Demonstrate how to use various Telepsychiatry techniques
  • Summarize legal, licensure and ethical issues with Telepsychiatry
  • Develop treatment strategies for patients diagnosed with bipolar depression.
  • Develop treatment strategies for patients diagnosed with major depression.
  • Discuss the clinical efficacy and safety data regarding patience diagnosed with psychiatric disorders.
  • Develop treatment strategies for patients diagnosed with OCD, with and without comorbidities.
  • Evaluate current and emerging treatment strategies for diagnosed with attention deficit hyperactivity disorders.
  • Discuss anxiety disorders in patients of all age spans and their treatments.
  • Select an optimal treatment strategy for patients diagnosed with psychosis.
  • Compare medications and treatment for patients with various sleep disorders.


Follow Us

Jointly Provided By